Alpha 2.0
Login Register
» Authors » Benjamin Schwalm

Benjamin Schwalm

Explore the profile of Benjamin Schwalm including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 255
Followers 0
Related Specialties
Molecular Biology
Oncology
General Medicine
Top 10 Co-Authors
Marcel Kool
Stefan M Pfister
Sebastian Brabetz
Andrey Korshunov
Norman L Mack
Till Milde
Olaf Witt
Volker Hovestadt
Sonja Krausert
Peter Lichter
Published In
Neuro Oncol
Cancer Cell
EMBO Mol Med
Nat Med
Int J Mol Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments
Lago C, Federico A, Leva G, Mack N, Schwalm B, Ballabio C, et al.
EMBO Mol Med . 2023 Dec; 15(12):e18199. PMID: 38037472
Brain tumors are the leading cause of cancer-related death in children. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of pediatric brain cancers are limited and...
2.
Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma
Krausert S, Brabetz S, Mack N, Schmitt-Hoffner F, Schwalm B, Peterziel H, et al.
Neurooncol Adv . 2022 Apr; 4(1):vdac026. PMID: 35475274
Background: Inhibition of the sonic hedgehog (SHH) pathway with Smoothened (SMO) inhibitors is a promising treatment strategy in SHH-activated medulloblastoma, especially in adult patients. However, the problem is that tumors...
3.
Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir
Gringmuth M, Walther J, Greiser S, Toussaint M, Schwalm B, Kool M, et al.
Int J Mol Sci . 2022 Apr; 23(7). PMID: 35409174
Children with high-risk SHH/-mut and Group 3 medulloblastoma (MB) have a 5-year overall survival of only 40%. Innovative approaches to enhance survival while preventing adverse effects are urgently needed. We...
4.
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma
Gojo J, Englinger B, Jiang L, Hubner J, Shaw M, Hack O, et al.
Cancer Cell . 2020 Jul; 38(1):44-59.e9. PMID: 32663469
Ependymoma is a heterogeneous entity of central nervous system tumors with well-established molecular groups. Here, we apply single-cell RNA sequencing to analyze ependymomas across molecular groups and anatomic locations to...
5.
The molecular landscape of ETMR at diagnosis and relapse
Lambo S, Grobner S, Rausch T, Waszak S, Schmidt C, Gorthi A, et al.
Nature . 2019 Dec; 576(7786):274-280. PMID: 31802000
Embryonal tumours with multilayered rosettes (ETMRs) are aggressive paediatric embryonal brain tumours with a universally poor prognosis. Here we collected 193 primary ETMRs and 23 matched relapse samples to investigate...
6.
A biobank of patient-derived pediatric brain tumor models
Brabetz S, Leary S, Grobner S, Nakamoto M, Seker-Cin H, Girard E, et al.
Nat Med . 2018 Oct; 24(11):1752-1761. PMID: 30349086
Brain tumors are the leading cause of cancer-related death in children. Genomic studies have provided insights into molecular subgroups and oncogenic drivers of pediatric brain tumors that may lead to...
7.
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients
Schmidt C, Schubert N, Brabetz S, Mack N, Schwalm B, Chan J, et al.
Neuro Oncol . 2017 May; 19(12):1607-1617. PMID: 28482026
Background: Embryonal tumor with multilayered rosettes (ETMR) is a rare and aggressive embryonal brain tumor that solely occurs in infants and young children and has only recently been recognized as...